Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (2538)	10/28/1997 3:51:00 PM
From: Izzy	Read Replies (2) \| Respond to of 6136

Henry: Thanks for post. AGPH is on a real run (up 4+ so far; 8 point spread for the day). For the heck of it, bought BCHE (has new combo pill--3TC/AZT). Henry, you got to start buying some of these stocks; LGND seems flat.

To: Henry Niman who wrote (2538)	10/29/1997 6:39:00 PM
From: Timothy Kross	Read Replies (1) \| Respond to of 6136

Henry, I have followed your postings on the Ligand thread. You mentioned that you do not own any Agouron stock. You have shared very valuable scientific information in the past and I would like to return the favor. There is an excellent scientific review of structural based drug design (SBDD) in the April'97 issue of Seminars in Oncology. The reference is Semin Oncol 24: 164-172. The author is Robert C. Jackson, PhD. Reprints of his review paper can be obtained by writing to him at the following address: Robert C. Jackson, PHD. Agouron Pharmaceuticals, Inc. 3565 General Atomics Court San Diego, Ca. 92121 This particular issue deals with SBDD and the future of new therapeutics on the oncological horizon. The specific title of that issue is "New Sources and New Antitumor Drugs in Development". Dr. Jackson's chapter deals with the horizon of new drugs that include thymidylate synthetase inhibitors (TS), glycinamide ribonucleotide formyltransferase inhibitors (GARFT), and the matrix metalloprotease inhibitors (MMP). He talks about drugs in these categories that include AG 337 (Thymitaq), AG 2034, and AG 3340, respectively. His review and references are excellent, giving the historical and scientific background behind the birth and development of SBDD. I think that this reference article is quite auspicious for Agouron Pharmaceuticals. This peer reviewed journal has asked a scientist from Agouron to give the community of practicing oncologists a look ahead at what is on the horizon of new drug development . And so what does Dr. Jackson talk about. He gives the entire overview of development in the areas of TS, GARFT, and MMP inhibitor development. My take of the article is that there is Agouron and then there is everybody else. They had virtually a lock on the oncological drug pipeline that is being developed by SBDD. I think you will enjoy the article, its content, and its scope of knowledge and references. Once you have reviewed this article, please give me your reasons for not investing in Agouron Pharmaceuticals. I would appreciate your thoughts. Best regards, TJK.